Helicobacter pylori CagA protein is a potent and broad-spectrum amyloid inhibitor
Zhen Jin1, William Pallisgaard Olsen2, Cecilia Mörman1,3
1Department of Medicine, Huddinge, Karolinska Institutet, 14183 Huddinge, Sweden.
Abstract:
Bacteria, the smallest and most abundant life forms on Earth, have been a source of insights that have had a considerable impact on human health. Helicobacter pylori has captured substantial attention due to its role in provoking an array of gastrointestinal ailments and other human diseases. Here, we report that H. pylori releases the protein CagA (cytotoxin-associated gene A) that strongly inhibits formation of both functional (bacterial biofilm) and pathogenic amyloid assemblies by targeting various stages during fibril formation. CagA's broad substrate specificity reveals a mechanism whereby H. pylori interferes with other bacteria and humans, offering approaches to combat bacterial infections and human protein misfolding diseases.
Insights
Helicobacter pylori releases CagA protein, inhibiting bacterial biofilms and pathogenic amyloid formation. This discovery offers new strategies for combating bacterial infections and human protein misfolding diseases.
Area of Science:
- Microbiology
- Molecular Biology
- Biochemistry
Background:
- Bacteria are abundant life forms impacting human health.
- Helicobacter pylori is linked to gastrointestinal ailments and other diseases.
- Protein aggregation is implicated in various human diseases.
Purpose of the Study:
- To investigate the role of Helicobacter pylori protein CagA in modulating protein assembly.
- To determine CagA's effect on bacterial biofilm and human amyloid formation.
- To explore potential therapeutic applications of CagA.
Main Methods:
- Investigated the interaction of CagA with protein fibril formation.
- Assessed CagA's inhibitory effects on bacterial biofilm assembly.
- Analyzed CagA's impact on pathogenic amyloid formation in human disease models.
Main Results:
- H. pylori releases CagA protein.
- CagA strongly inhibits the formation of bacterial biofilms.
- CagA also inhibits the formation of pathogenic amyloid assemblies.
- CagA exhibits broad substrate specificity, affecting various stages of fibril formation.
Conclusions:
- H. pylori's CagA protein interferes with both bacterial and human protein aggregation.
- This mechanism provides novel approaches to combat bacterial infections.
- CagA offers potential therapeutic strategies for human protein misfolding diseases.
More Related Videos
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...